2-(4-吗啡啉基)嘧啶-5-硼酸嚬哪醇酯 | 957198-30-0

• 物质功能分类: 医药中间体 - 杂环化合物 - 酯类 - 嘧啶类化合物
• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 2-(4-吗啡啉基)嘧啶-5-硼酸嚬哪醇酯
• 中文别名: 2-(4-吗啉基)嘧啶-5-硼酸频哪醇酯
• 英文名称: 4-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-yl)morpholine
• 英文别名: 2-(4-morpholino)pyrimidine-5-boronic acid pinacol ester；4-[5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-yl]morpholine
• CAS: 957198-30-0
• 化学式: C₁₄H₂₂BN₃O₃
• 分子量: 291.158
• InChiKey: HNVAYPJNFUXYII-UHFFFAOYSA-N

物化性质

• 密度：
  1.16

计算性质

• 辛醇/水分配系数(LogP)：
  0.61
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  56.7
• 氢给体数：
  0
• 氢受体数：
  6

安全信息

• 危险品标志：
  Xn
• 危险类别码：
  R22
• 海关编码：
  2934999090
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302
• 储存条件：
  2-8°C

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-(4-Morpholino)pyrimidine-5-boronic acid pinacol ester
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-(4-Morpholino)pyrimidine-5-boronic acid pinacol ester
CAS number: 957198-30-0

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C14H22BN3O3
Molecular weight: 291.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-(4-吗啡啉基)嘧啶-5-硼酸嚬哪醇酯 在 四(三苯基膦)钯 、 sodium carbonate 、 1-丙基磷酸酐 、 N,N-二异丙基乙胺 作用下， 以 水 、 二甲基亚砜 、 乙酸乙酯 为溶剂， 反应 21.5h， 生成 3-{3-[4-({N-[(trans-4-{[(tert-butoxycarbonyl)amino]methyl}cyclohexyl)carbonyl]-3-[2-(morpholin-4-yl)pyrimidin-5-yl]-L-phenylalanyl}amino)phenyl]-1H-1,2,4-triazol-5-yl}-2,2,3,3-tetrafluoropropanoic acid
  参考文献：
  名称：

  SUBSTITUTED PHENYLALANINE DERIVATIVES

  摘要：

  本发明涉及取代苯丙氨酸衍生物及其制备方法，以及将其用于生产用于治疗和/或预防疾病的药物，特别是心血管疾病和/或严重围手术期失血的药物。

  公开号：

  US20160244437A1
• 作为产物：
  描述：

  5-溴-2-(吗啉-1)嘧啶 、 联硼酸频那醇酯 在 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 、 potassium acetate 作用下， 以 1,4-二氧六环 为溶剂， 以65.7%的产率得到2-(4-吗啡啉基)嘧啶-5-硼酸嚬哪醇酯
  参考文献：
  名称：

  [EN] 1,2,4-TRIAZOLE DERIVATIVE AND PREPARATION METHOD THEREFOR AND USE THEREOF
  [FR] DÉRIVÉ DE 1,2,4-TRIAZOLE, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION
  [ZH] 1,2,4-三氮唑衍生物及其制备方法和用途

  摘要：

  提供一种1,2,4-三氮唑衍生物及其制备方法和用途，所述1,2,4-三氮唑衍生物为式I所示的化合物，或其旋光异构体、对映体、非对映体、外消旋体或外消旋混合物，或其溶剂合物、前药，或其药学上可接受的盐；所述的化合物可用于治疗多种不当的核转运触发的异常细胞应答相关的疾病、紊乱或病症。

  公开号：

  WO2022089629A1

文献信息

• [EN] INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING<br/>[FR] INHIBITEURS DE LA LIAISON PROTÉINE WDR5-PROTÉINE
  申请人：PROPELLON THERAPEUTICS INC

  公开号：WO2019046944A1

  公开（公告）日：2019-03-14

  The present application is directed to compounds of Formula I: (I) compositions comprising these compounds and their uses, for example as medicaments for the treatment of diseases, disorders or conditions mediated or treatable by inhibition of binding between WDR5 protein and its binding partners.

  本申请涉及到Formula I的化合物：(I) 包括这些化合物的组合物及其用途，例如作为治疗由于抑制WDR5蛋白与其结合伙伴之间结合而介导或可治疗的疾病、紊乱或状况的药物。
• [EN] TRICYCLIC MODULATORS OF TNF SIGNALING<br/>[FR] MODULATEURS TRICYCLIQUES DE LA SIGNALISATION DU TNF
  申请人：ABBVIE INC

  公开号：WO2016168641A1

  公开（公告）日：2016-10-20

  The invention provides tricyclic heterocyclic compounds, pharmaceutically acceptable salts, prodrugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the invention may be useful for treating immunological and oncological conditions.

  这项发明提供了三环杂环化合物，其药用盐、前药、生物活性代谢物、立体异构体和同分异构体，其中变量在此处定义。该发明的化合物可能对治疗免疫和肿瘤疾病有用。
• 溴二氟甲硫氧基类化合物、中间体，及其制备 方法和应用
  申请人：中国科学院上海有机化学研究所

  公开号：CN107011219B

  公开（公告）日：2018-11-27

  本发明公开了一种溴二氟甲硫氧基类化合物、中间体，及其制备方法及其应用。本发明提供了一种化合物I，其中，R1、R2和R3各自独立地为H、C1～C10的烷基、C6～C10的芳基，且R1、R2和R3中至少两个不同时为H；或所述的R1、R2和R3中任意两个连接，形成C3～C6的环烷烃；或所述的R1、R2和R3中任意两个连接，形成C3～C6的环烷烃，并与苯环形成并环。本发明提供了一种所述的化合物I的制备方法，其包括如下步骤：在有机溶剂中，将化合物II、Cl2和化合物III进行反应，得到所述的化合物I即可。使用本发明的溴二氟甲硫氧基类化合物I，能实现芳烃或杂芳烃化合物上直接引入溴二氟甲硫基。
• Synthesis and Reactivity of α‐Cumyl Bromodifluoromethanesulfenate: Application to the Radiosynthesis of [ ¹⁸ F]ArylSCF ₃
  作者：Jiang Wu、Qunchao Zhao、Thomas C. Wilson、Stefan Verhoog、Long Lu、Véronique Gouverneur、Qilong Shen

  DOI：10.1002/anie.201813708

  日期：2019.2.18

  A highly reactive electrophilic bromodifluoromethylthiolating reagent, α-cumyl bromodifluoro-methanesulfenate 1, was prepared to allow for direct bromodifluoromethylthiolation of aryl boron reagents. This coupling reaction takes place under copper catalysis, and affords a large range of bromodifluoromethylthiolated arenes. These compounds are amenable to various transformations including halogen exchange

  制备了高反应性的亲电溴二氟甲基硫醇化试剂，α-枯基溴二氟甲基甲磺酸盐1，以允许芳基硼试剂的直接溴二氟甲基硫醇化。该偶联反应在铜催化下发生，并提供了大范围的溴二氟甲基硫醇化的芳烃。这些化合物可进行各种转化，包括与[18 F] KF / K222进行卤素交换，该过程可从相应的芳基硼酸频哪醇酯分两步获得[18 F]芳基SCF3。
• [EN] PHENYL ALKANOIC ACID DERIVATIVES AS GPR AGONISTS<br/>[FR] DÉRIVÉS D'ACIDE PHÉNYLALCANOÏQUE EN TANT QU'AGONISTES DU RPG
  申请人：PIRAMAL ENTPR LTD

  公开号：WO2013128378A1

  公开（公告）日：2013-09-06

  The present invention relates to phenyl alkanoic acid derivatives (the compounds of Formula (I)); and their isotopic forms, stereoisomeric and tautomeric forms and mixtures thereof in all ratios, or pharmaceutically acceptable salts, pharmaceutically acceptable solvates, prodrugs, polymorphs, N-oxides, S-oxides or carboxylic acid isosteres thereof. The invention also relates to processes for the preparation of compounds of Formula (I) and pharmaceutical compositions comprising one or more of the compounds of Formula (I). The said compounds and the pharmaceutical composition function as GPR (G-protein coupled receptor) agonists, particularly as GPR40 agonists, and are useful in the treatment of diseases or conditions mediated by GPR40. The present invention further relates to a method of treatment of diseases or conditions mediated by GPR40comprising administering to a subject in need thereof a therapeutically effective amount of the compounds of Formula (I).

  本发明涉及苯基烷酸衍生物（公式(I)的化合物）；及其同位素形式、立体异构体、互变异构体和所有比例的混合物，或其药物可接受的盐、药物可接受的溶剂化物、前药、多态性、N-氧化物、S-氧化物或羧酸的等排体。本发明还涉及制备公式(I)化合物的方法和包含一个或多个公式(I)化合物的药物组合物。所述化合物和药物组合物作为GPR（G蛋白偶联受体）激动剂，特别是作为GPR40激动剂，并且可用于治疗由GPR40介导的疾病或状况。本发明进一步涉及一种治疗由GPR40介导的疾病或状况的方法，包括向需要治疗的受试者施用治疗有效量的公式(I)化合物。